Pathology Flashcards
Hypertrophy
Increase in structural proteins and organelles -> increase in size of cells.
Hyperplasia
Controlled proliferation of stem cells and differentiated cells -> increase in number of cells. Excessive stimulation -> pathologic hyperplasia (eg, endometrial hyperplasia), which may progress to dysplasia and cancer
Atrophy
decrease in tissue mass due to decrease in size (increase cytoskeleton degradation via ubiquitin-proteasome pathway and autophagy; decrease protein synthesis) and/or number of cells (apoptosis). Causes include disuse, denervation, loss of blood supply, loss of hormonal stimulation, poor nutrition.
Metaplasia
Reprogramming of stem cells -> replacement of one cell type by another that can adapt to a new stress. Usually due to exposure to an irritant, such as gastric acid (-> Barrett esophagus) or cigarette smoke (-> respiratory ciliated columnar epithelium replaced by stratified squamous epithelium). May progress to dysplasia -> malignant transformation with persistent insult (eg, Barrett esophagus -> esophageal adenocarcinoma). Metaplasia of connective tissue can also occur (mg, myositis ossificans, the formation of bone within muscle after trauma).
Dysplasia
Disordered, precancerous epithelial cell growth; not considered a true adaptive response. Characterized by loss of uniformity of cell size and shape (pleomorphism); loss of tissue orientation; nuclear changes (eg, increased nuclear: cytoplasmic ratio and clumped chromatin). Milk and moderate dysplasias (ie, do not involve entire thickness of epithelium) may regress with alleviation of inciting cause. Severe dysplasia often becomes irreversible and progresses to carcinoma in situ. Usually preceded by persistent metaplasia or pathologic hyperplasia.
Carcinoma
malignant tumor of epithelial origin
Sarcoma
malignant tumor of mesenchymal origin
Adenoma
Benign tumor, epithelium cell type
Papilloma
Benign tumor, epithelium cell type
Adenocarcinoma
Malignant tumor, epithelium cell type
Papillary Carcinoma
Malignant tumor, epithelium cell type
Hemangioma
Benign tumor, mesenchyme cells in blood vessels
Leiomyoma
Benign tumor, mesenchyme cells in smooth muscle
Rhabdomyoma
Benign tumor, mesenchyme cells in striated muscle
Fibroma
Benign tumor, mesenchyme cells in connective tissue
Osteoma
Benign tumor, mesenchyme cells in bone
Nevus/mole
Benign tumor, mesenchyme cells in melanocyte
Lipoma
Benign tumor, mesenchyme cells in fat
Leukemia
Malignant tumor, mesenchyme cells in blood cells
Lymphoma
Malignant tumor, mesenchyme cells in blood cells
Angiosarcoma
Malignant tumor, mesenchyme cells in blood vessels
Leiomyosarcoma
Malignant tumor, mesenchyme cells in smooth muscle
Rhabdomyosarcoma
Malignant tumor, mesenchyme cells in striated muscle
Fibrosarcoma
Malignant tumor, mesenchyme cells in connective tissue
Osteosarcoma
Malignant tumor, mesenchyme cells in bone
Liposarcoma
Malignant tumor, mesenchyme cells in fat
Melanoma
Malignant tumor, mesenchyme cells in melanocytes
Tumor Grade
Degree of cellular differentiation and mitotic activity on histology. Ranges from low grade (well-differentiated) to high grade (poorly differentiated, undifferentiated or anaplastic)
Tumor Stage
Degree of localization/spread based on site and size of primary lesion, spread to regional lymph nodes, presence of metastases. TNM staging T=Tumor size/invasiveness N=Node involvement M=Metastases
ALK
oncogene
lung adenocarcinoma
BCR-ABL
oncogene
CML, ALL
BCL-2
oncogene
follicular and diffuse large B call lymphoma
BRAF
oncogene
melanoma, non-Hodgkin lymphoma, papillary thyroid carcinoma, hairy cell leukemia
c-KIT
oncogene
gastrointestinal stromal tumor (GIST)
c-MYC
oncogene
Burkitt lymphoma
HER2/neu (c-erbB2)
oncogene
Breast and gastric carcinomas
JAK2
oncogene
Chronic myeloproliferative disorders
KRAS
oncogene
colon cancer, lung cancer, pancreatic cancer
MYCL1
oncogene
lung tumor
N-myc (MYCN)
oncogene
neuroblastoma
RET
oncogene
MEN 2A and 2B, papillary thyroid carcinoma, pheochromocytoma
APC
tumor suppressor gene colorectal cancer (associated with FAP)
BRCA1/BRCA2
tumor suppressor gene
Breast, ovarian, and pancreatic cancers
CDKN2A
tumor suppressor gene
melanoma, pancreatic cancer
DCC
tumor suppressor gene
colon cancer
SMAD4 (DPC4)
tumor suppressor gene
pancreatic cancer
MEN1
tumor suppressor gene
multiple endocrine neoplasia type 1
NF1
tumor suppressor gene
neurofibromatosis type 1
NF2
tumor suppressor gene
neurofibromatosis type 2
PTEN
tumor suppressor gene
prostate, breast, and endometrial cancers
Rb
tumor suppressor gene
retinoblastoma, osteosarcoma (bone cancer)
TP53
tumor suppressor gene
most human cancers, Li-Fraumeni syndrome
TSC1
tumor suppressor gene
tuberous sclerosis
TSC2
tumor suppressor gene
tuberous sclerosis
VHL
tumor suppressor gene
von Hippel-Lindau disease
WT1
tumor suppressor gene Wilms tumor (nephroblastoma)